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Abstract
Background: Prior to 2007, highly pathogenic avian influenza (HPAI) H5N1 viruses isolated from poultry and humans in
Vietnam were consistently reported to be clade 1 viruses, susceptible to oseltamivir but resistant to amantadine. Here we
describe the re-emergence of human HPAI H5N1 virus infections in Vietnam in 2007 and the characteristics of the isolated
viruses.
Methods and Findings: Respiratory specimens from patients suspected to be infected with avian influenza in 2007 were
screened by influenza and H5 subtype specific polymerase chain reaction. Isolated H5N1 strains were further characterized
by genome sequencing and drug susceptibility testing. Eleven poultry outbreak isolates from 2007 were included in the
sequence analysis. Eight patients, all of them from northern Vietnam, were diagnosed with H5N1 in 2007 and five of them
died. Phylogenetic analysis of H5N1 viruses isolated from humans and poultry in 2007 showed that clade 2.3.4 H5N1 viruses
replaced clade 1 viruses in northern Vietnam. Four human H5N1 strains had eight-fold reduced in-vitro susceptibility to
oseltamivir as compared to clade 1 viruses. In two poultry isolates the I117V mutation was found in the neuraminidase gene,
which is associated with reduced susceptibility to oseltamivir. No mutations in the M2 gene conferring amantadine
resistance were found.
Conclusion: In 2007, H5N1 clade 2.3.4 viruses replaced clade 1 viruses in northern Vietnam and were susceptible to
amantadine but showed reduced susceptibility to oseltamivir. Combination antiviral therapy with oseltamivir and
amantadine for human cases in Vietnam is recommended.
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Introduction
The host specificity of avian influenza A (H5N1) viruses is
generally restricted to birds but occasionally these viruses cross the
species barrier to infect mammals, including humans [1]. Since
2003, a total of 373 human infections with highly pathogenic avian
influenza (HPAI) virus have been reported to the WHO, of which
236 have been fatal (www.who.int, accessed 24-3-2008). The
actual number of cases may be much higher as most infected
people live in rural areas with poor access to healthcare and
appropriate diagnostic tests.
The genetic plasticity of influenza viruses and previous
experience with avian virus-derived human influenza pandemics
are the major reasons why the current pandemic of influenza A
subtype H5N1 in poultry and wild birds is perceived as such a
potential threat to human health. In response to this threat,
nations worldwide have based their national contingency plans on
the stockpiling of anti-influenza drugs and initiated major efforts to
develop H5N1 vaccines. However, the effectiveness of these two
strategies will depend on the susceptibility of the pandemic strain,
should it emerge, to the stockpiled drugs and the protective
immune response elicited by vaccines against the current H5N1
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3339strains. The divergence of influenza H5N1 viruses into several
clades challenges these efforts.[2] To date, 10 different genetic
clades have been distinguished, some of which have a distinct
geographical distribution. The most diverse clade, clade 2, can be
subdivided into 5 subclades. Human infections have been caused
by (sub)clades 1, 2.1, 2.2, 2.3 and 7 [3].
Between 2003 and 2005, influenza H5N1 outbreaks in poultry
and humans in Vietnam were caused by clade 1 viruses [3–5].
These viruses were typically resistant to amantadine but
susceptible to oseltamivir [3,6], although the emergence of
oseltamivir resistant strains in patients during treatment has been
reported [7,8]. Like most other countries, Vietnam has stockpiled
oseltamivir for use in the event of a pandemic. Furthermore,
Vietnam has developed a prototype reverse genetics-generated
human H5N1 vaccine derived from a clade 1 H5N1 influenza
isolate (A/Vietnam/1194/2004).
In 2005 Vietnam started nation-wide poultry vaccination
programs which may have contributed to the absence of
widespread poultry outbreaks and human infections throughout
2006 [9]. However, in 2007, human infections with HPAI H5N1
viruses began to reappear in northern Vietnam coincident with
outbreaks in poultry and waterfowl. The situation regarding
poultry outbreaks was described recently, but data on the human
cases and their strain characterization are still lacking [5]. Here,
we report the clinical characteristics and outcome of patients
infected with H5N1 viruses emerging in Vietnam in 2007. H5N1
strains isolated from the human cases were genetically character-
ized and susceptibility to neuraminidase inhibitors and amanta-
dine were assessed.
Methods
Influenza diagnostics
Throat swabs or tracheal aspirates were collected on admission
from patients with clinically suspected H5N1 infection in northern
Vietnam and sent to the National Institute of Hygiene and
Epidemiology (NIHE) for the detection of influenza A H5N1 virus
using reverse transcriptase polymerase chain reaction (RT PCR)
and viral culture [10]. The national case definition for suspected
H5N1 infection is: sudden onset of fever.38uC; difficulty in
breathing; infiltrates on the chest X-ray; and a low total leucocyte
count in blood. Additional clinical specimens (rectal swabs, blood,
pleural fluid), from suspected or confirmed patients that were
admitted to the National Hospital of Pediatrics, National Institute
of Infectious and Tropical Diseases, and Bach Mai Hospital, all
situated in Hanoi, were tested by real time RT PCR and virus
isolation at the Oxford University Clinical Research Unit
(OUCRU) in Vietnam and at NIHE [11].
For virus isolation, clinical specimens were inoculated onto
Madin-Darby Canine Kidney (MDCK) cells in biosafety level 3
laboratories. Virus isolates were identified by RT PCR and
hemagglutination inhibition (HAI) with reference antiserum to A/
Duck/Hong Kong/820/80 (H5N3). In vitro susceptibility of virus
isolates to oseltamivir carboxylate was determined by a chemilu-
miniscent neuraminidase inhibition assay (NA-Star, Applied
Biosystems) and to zanamivir by fluorescent neuraminidase
inhibition assay, as described previously [12,13]. A total of 16
virus isolates were tested by neuraminidase inhibition assay: four
available human H5N1 strains from 2007, 11 human clade 1
H5N1 viruses isolated in Vietnam between 2004 and 2005, and
one human clade 2.3.4 H5N1 strain isolated in Vietnam in 2005.
Specimens and strains were stored at 280uC.
Acute and convalescent sera from the first three patients were
tested for the presence of H5-specific antibodies by hemaggluti-
nation inhibition assay (HAI) using chicken red blood cells and
clade 1 (A/Hanoi 3040/2004) and clade 2.3.4 virus (A/Hanoi
31244/2007) antigens. While it is recognised that horse red blood
cells are optimal for detecting human antibody responses to H5N1
viruses, horse red blood cells were not readily available in
Vietnam.
Sequencing and phylogenetic analysis
Sequence analysis of the HA gene was performed on six human
H5N1 isolates and 11 poultry isolates obtained in 2007. Viral
RNA was extracted from virus isolates by use of an RNA
extraction kit (QIAamp, Qiagen, Netherlands), according to the
manufacturer’s protocol. cDNA was synthesized using the A-U12
primer (59-AGCAAAAGCAGG-39), which is complementary to
the 39 end of the viral RNA, and reverse transcriptase (SuperScript
III; Invitrogen, USA) according to the manufacturer’s protocol.
The resultant cDNA products were used to amplify the
hemagglutinin (HA) gene by a standard PCR method (Proof Start
DNA Polymerase; Qiagen, Netherlands) with the following primer
pair: H5F: AGC AAA AGC AGG GGT TCA ATC TGT CAA
AAT GG and H5R: AGT AGA AAC AAG GGT GTT TTT
AAC TAC AAT CTG.
Purified PCR products were sequenced using BigDye Termi-
nator version 3.1 Cycle Sequencing Kit on an ABI 3100 Genetic
Analyzer (Applied Biosystems, CA, USA) following the manufac-
turer’s instructions. Haemagglutinin sequences of poultry and
human isolates were phylogenetically analyzed together with
representative virus sequences available in GenBank, including
vaccine candidate strains. Phylogenetic trees of the HA gene
segment were created using the maximum likelihood method
available in DNASIS-MAX version 02–06 (Hitachi-Japan).
Neuraminidase and M2 gene sequencing was performed to assess
mutations coding for oseltamivir and amantadine resistance,
respectively. The following primers were used for this purpose:
NA-534F: TTG CTT GGT CAG CAA GTG C and NA-1149R:
TCT GTC CAT CCA TTA GGA TCC for neuraminidase gene
and M2F: CTA GTC AGG CCA GGC AAA TG and M2R:
ACT GTC GTC AGC ATC CAC AG for M2 gene.
Neuraminidase gene sequencing was performed both on human
and poultry H5N1 isolates, and M2 sequencing only on human
H5N1 isolates.
Results
In 2007, a total of 295 clinical specimens collected from 251
patients in northern Vietnam with suspected H5N1 infection, were
tested by RT-PCR at NIHE. Of these, H5N1 infection was
confirmed in a total of eight (3.2%) patients: six males and two
females (median age 23 y, range: 4–30 y, Table 1). One patient
(patient 6) was seven months pregnant. Seven of the patients
reported exposure to poultry prior to onset of illness, and five lived
in an area with reported poultry outbreaks (Figure 1). Human
infections occurred between the start of May 2007 and mid
December 2007. The median time: (i) from illness onset to
admission was 6 days (range: 4–8), (ii) from admission to discharge
or death 5.5 days (range: 1–41), and (iii) from disease onset to
death 10 days (range: 7–19). The patients were admitted to four
different hospitals in northern Vietnam. No human case was
epidemiologically linked with another.
Clinical features
All patients presented with fever, cough and dyspnea. Mean
oxygen saturation was 81% (range: 40–93%) at admission.
Pleuritic chest pain was reported by all but one patient in whom
H5N1 in Vietnam
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Diarrhea was reported in three patients. Conjunctivitis was not a
clinical feature. Chest X rays showed bilateral pulmonary
infiltration in all patients. Median total leucocyte counts and
lymphocyte counts were 4,100 cells/mm3 (range: 2,000–28,700)
and 750 cells/mm3 (range: 300–1,700), respectively. The median
platelet count was 117,000/mm3 (range: 87,000–164,000). Seven
patients required mechanical ventilation early after admission.
One patient that survived (patient 3) only received supplemental
oxygen and did not require mechanical ventilation. Five patients
developed ARDS and pneumothoraces, and in three cases pleural
effusion was noted.
Treatment and outcome
Oseltamivir was administered to all patients within 3 days of
admission, corresponding to 5 to 9 days after onset of illness
(median: 8 days). After the first two cases had been diagnosed, the
time from admission to oseltamivir treatment was reduced from
three days to less than one day due to increased awareness. Despite
oseltamivir treatment, the mortality was high: 62,5% (5/8). The
median time from admission to death was 2 days (range: 1–13).
Patient 4 had a very high leucocyte count of 28,700 cells/mm3
and died within 2 days of admission. Aspergillus fumigatus was
cultured from his sputum. Patient 5 developed ventilator
associated pneumonia (VAP) with Acinetobacter spp and had
undetectable levels of influenza RNA at the time of death, 13
days after admission. All patients received low dose steroids during
their admission.
All survivors were admitted in May 2007, but originated from
different geographical areas (Figure 1). The fatal cases were all
admitted between June and December 2007. Compared to those
who died, survivors presented earlier to the hospital after illness
onset: median of 5 days versus 6 days (Mann-Whitney U test:
P=0.021) and had better oxygenation parameters at admission:
mean breathing rate of 28/min and 42/min (Mann-Whitney U
test: P=0.074).
Figure 1. Mapping of poultry and human H5N1 cases in northern Vietnam, 2007.
doi:10.1371/journal.pone.0003339.g001
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Quantitative influenza RT PCR data were available from four
patients: highest viral loads were found in specimens originating
from trachea or throat (obtained 6 to 11 days after onset of
symptoms), with viral loads ranging from 1.2610e5 to 1.1610e6
cDNA copies/mL. Viral RNA could be detected in the plasma
(obtained 7 to 9 days after disease onset) of three of five patients
tested (mean viral load: 5.2610e3 cDNA copies/mL). All three
patients with influenza virus RNA in plasma died. Detectable
H5N1 RNA was also found in the pleural fluid from two patients
with effusions both of which were positive with viral influenza
RNA in plasma. Drug susceptibility testing of four virus isolates
showed mean IC50 values for oseltamivir and zanamivir of
3.1 nM (n=4) and 1.3 nM (n=3), respectively (Table 2). Viruses
isolated from sequential specimens obtained at admission and
three days later on therapy from one patient showed stable
susceptibilities to oseltamivir (IC50 4.75 and 3.86 nM respective-
ly). The mean oseltamivir IC50 for eleven clade 1 viruses isolated
from Vietnamese patients in 2004 and 2005 is 0.4 nM (range 0.04
to 1.1 nM), illustrating an eight-fold reduced susceptibility of clade
2.3.4 H5N1 viruses as compared to clade 1 viruses. We also tested
the oseltamivir IC50 from a clade 2.3.4 strain isolated in 2005 (A/
Vietnam/HN 30850/2005, see below), which was found to be
2.0 nM.
Sequence and phylogenetic analysis of the hemagglutinin gene
revealed that the isolated H5N1 viruses were clade 2.3.4 (Figure 2)
Table 2. Laboratory data of human H5N1 cases in Vietnam, 2007.
1 234 5 6 ^ 78
Sex, age (y) Male, 29 Male, 19 Male, 30 Male, 20 Female, 28 Female, 26 Male, 15 Male, 4
White cell count (/mm3) 5600 4100 4100 28700 2000 8400 3100 2300
Neutrophils (/mm3) 4800 3560 3200 NR 1550 7800 1920 900
Lymphocytes (/mm3) 600 460 900 1700 430 300 1180 1300
Platelets (610E3/mL) 87 115 96 132 164 119 108 154
Na (mmol/L) 129 148 normal* 131 141 139 142 141
K (mmol/L) 2.8 4.5 normal 4.3 4.3 3.1 4.7 3.2
Cl (mmol/L) 92 112 normal 95 107 110 ND 110
Glucose (mmol/L) 11.3 13 5.5 5.2 15.7 6.8 5.2 7.1
Creatinine (mmol/L) 128 104 126 32 125 73 102 42.6
AST (U/L) 228 723 82 61 387 199 561 399.9
ALT (U/L) 89 684 70 55 113 45 205 63.2
LDH (U/L) ND 2418 ND 2236 3248 ND ND ND
pH 7.53 7.5 ND 7.46 7.48 7.472 ND 7.35
PaCO2 (mmHg) 29.5 31.6 ND 35.6 39.9 26.8 ND 42
PaO2 (mmHg) 48.9 61 ND 61 37 38.4 ND 31.1
HCO3 (mmol/L) 24.9 24.6 ND 25.2 ND 19.8 ND 20.6
O2 saturation (%) 84 88 93 92 91 82 ND 40
Virus isolated Y N RN RY Y Y Y Y
IC50 OST (nM) ND ND ND 2.7 3.2 2.5 3.8 ND
IC50 ZNV (nM) ND ND ND 1.3 1.2 1.3 ND ND
Influenza RTPCR {
nose swab/NPA NEG POS ND ND POS 25 ND ND
throat/tracheal asp 3.1610E5 POS POS 1.2610E5 POS 1.1610E6 POS POS
rectum NEG NEG ND ND ND 3.2610E4 ND ND
plasma NEG NEG ND NEG 3.1610E3 7.3610E3 ND POS
pleural fluid 1.4610E2 2.7610E4
Serology
Clade 1 antigen
1st serum NEG NEG NEG ND ND ND ND ND
2nd serum NEG NEG 1:10 ND ND ND ND ND
Clade 2 antigen
1st serum Clade 2.3 1:20 1:10 1:20 ND ND ND ND ND
2nd serum Clade 2.3 1:160 1:160 1:320 ND ND ND ND ND
^pregnant.
ND: not done.
*within normal range.
{if available, quantitative viral loads are presented (cDNA copies/mL).
doi:10.1371/journal.pone.0003339.t002
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PLoS ONE | www.plosone.org 5 October 2008 | Volume 3 | Issue 10 | e3339Figure 2. Phylogenetic analysis of hemagglutinin gene sequence of Influenza A H5N1 in humans and poultry in Vietnam 2007 and
sequences downloaded from genebank. The numbers to the right of the figure refer to the World Health Organization H5N1 clade designations.
doi:10.1371/journal.pone.0003339.g002
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2005 to be clade 2.3.4 as well (Figure 2). A polybasic cleavage site
motif was present in the HA gene of all sequenced strains.
Compared to A/Anhui/1/05 (the current vaccine candidate for
clade 2.3), there were 5 to 10 amino acid differences in the HA
protein of A/Vietnam/2007 virus (data not shown), which
translates to ,98% homology. In all human H5N1 isolates, no
mutations resulting in amino acid substitutions that confer
amantadine resistance were found in the M2 gene (L26F, V27A,
A30T, S31N, and G34E). In the neuraminidase gene no H274Y
or N294S substitution was found. However, in two poultry isolates
the I117V substitution was found, conferring reduced susceptibil-
ity to oseltamivir.
Discussion
Here we report on human A H5N1 virus clade 2.3.4 infections
in northern Vietnam in 2007. During the same period, clade 1
viruses continued to circulate in poultry in southern Vietnam but
did not cause any recognized human infections [5]. The co-
circulation of multiple sub lineages of influenza H5N1 in poultry
in Vietnam has been previously reported and suggested to have
been introduced from southern China where clade 2.3.4 was
already dominant [5]. Whilst the clinical presentation and case
fatality ratio of the eight patients infected with clade 2.3.4 avian
influenza were similar to earlier Vietnam H5N1 cases with clade 1
H5N1 viruses, there were important differences in the antiviral
drug susceptibility profile.
The clade 2.3.4 H5N1 strains isolated from four patients
showed up to eight-fold reductions in susceptibility to oseltamivir,
when compared to human H5N1 clade 1 strains. Additionally, we
showed that one clade 2.3.4 H5N1 virus isolated from a human in
2005 already had a reduced susceptibility to oseltamivir. These
levels of reduced susceptibility to oseltamivir are of uncertain
clinical significance, but may require higher dosing of oseltamivir
[15]. All patients in this report were treated with either standard or
double dose oseltamivir. It was striking that most patients were
brought to medical attention at a rather late stage of their illness
which resulted in a delayed initiation of oseltamivir treatment.
Better access to diagnostics and treatment in rural areas will help
in reducing this delay and will likely improve outcome [3].
Importantly, no amantadine resistance-conferring mutations
were observed in the clade 2.3.4 viruses isolated from these
patients, in contrast to clade 1 viruses, which are invariably
amantadine resistant, and clade 2.1 and 2.2 H5N1 viruses show
varying rates of resistance to the adamantanes [3,6,16]. Suscep-
tibility to amantadine allows the use of this agent in combination
therapy. Oseltamivir treatment in combination with amantadine
increases survival in a mouse model and has shown to be well
tolerated in healthy volunteers [17,18]. Combination therapy has
as an additional advantage that it may prevent the development of
resistance [19]. Therefore, amantadine combined with oseltamivir
needs to be considered in patients infected with amantadine
sensitive strains, as is also recommended by the WHO [18,20].
Monotherapy with amantadine should be avoided because of the
high risk of resistance development during treatment [21]. For the
same reason, the use of amantadine should be prohibited in
poultry farming because this will lead to the emergence of
amantadine resistant strains in the animal sector with implications
for the treatment of human infections [22]. However, the
implementation of such an empiric treatment policy in Vietnam
will be difficult as amantadine is not registered in Vietnam.
The co-circulation in Vietnam of two distinct highly pathogenic
H5N1 strains has important implications for both animal and
human health. By reassortment, clade 2.3.4 viruses may arise with
the internal gene constellation of clade 1 viruses, as has already
been observed in an H5N1 virus isolated from a duck in Vietnam
[5]. The emergence of a new clade with different antigenic
properties and antiviral susceptibilities than previous outbreak
strains in Vietnam in 2007, underscores the need for timely
surveillance with further characterization of isolated strains.
Though the I117V substitution was present in two poultry isolates,
no known mutation was found that could explain the reduced
susceptibility to oseltamivir in the four tested human H5N1 strains.
This finding emphasizes the importance of phenotypic analysis of
drug susceptibility. Since poultry outbreaks precede and outnum-
ber human cases, phenotypic analysis of drug susceptibility should
also be routinely conducted on poultry isolates. These data will
help the human health care sector with treatment considerations
accordingly in a timely fashion.
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